Literature DB >> 24140078

The impact of cefepime as first line therapy for neutropenic fever on Clostridium difficile rates among hematology and oncology patients.

Eavan G Muldoon1, Lauren Epstein, Tanya Logvinenko, Susan Murray, Shira I Doron, David R Snydman.   

Abstract

After changing empiric treatment of febrile neutropenia from meropenem to cefepime, the effect on Clostridium difficile infection (CDI) was investigated. The change was assessed using an autoregressive model. A significant increase in CDI rates occurred following the introduction of cefepime. There may be an association between increased cefepime usage and CDI.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimicrobial stewardship; Cefepime; Clostridium difficile; Neutropenic sepsis

Mesh：

Substances：

Year:  2013        PMID： 24140078      PMCID： PMC3876480          DOI： 10.1016/j.anaerobe.2013.10.001

Source DB:  PubMed          Journal:  Anaerobe        ISSN： 1075-9964            Impact factor:   3.331


  9 in total

1.  An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings.

Authors:  Mamoon A Aldeyab; Mary P Kearney; Michael G Scott; Motasem A Aldiab; Yaser M Alahmadi; Feras W Darwish Elhajji; Fidelma A Magee; James C McElnay
Journal:  J Antimicrob Chemother       Date:  2012-08-16       Impact factor: 5.790

2.  Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection.

Authors:  Moïra Joëlle Talpaert; Guduru Gopal Rao; Ben Symons Cooper; Paul Wade
Journal:  J Antimicrob Chemother       Date:  2011-06-14       Impact factor: 5.790

3.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.

Authors:  Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

4.  A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.

Authors:  E J Bow; C Rotstein; G A Noskin; M Laverdiere; A P Schwarer; B H Segal; J F Seymour; J Szer; S Sanche
Journal:  Clin Infect Dis       Date:  2006-07-10       Impact factor: 9.079

5.  A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use.

Authors:  Carlene A Muto; Marian Pokrywka; Kathleen Shutt; Aaron B Mendelsohn; Kathy Nouri; Kathy Posey; Terri Roberts; Karen Croyle; Sharon Krystofiak; Sujata Patel-Brown; A William Pasculle; David L Paterson; Melissa Saul; Lee H Harrison
Journal:  Infect Control Hosp Epidemiol       Date:  2005-03       Impact factor: 3.254

6.  Antibacterial activity of meropenem and selected comparative agents against anaerobic bacteria at seven North American centers.

Authors:  W Sheikh; D H Pitkin; H Nadler
Journal:  Clin Infect Dis       Date:  1993-06       Impact factor: 9.079

Review 7.  Antimicrobial-associated risk factors for Clostridium difficile infection.

Authors:  Robert C Owens; Curtis J Donskey; Robert P Gaynes; Vivian G Loo; Carlene A Muto
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

8.  Clostridium difficile--associated disease in a setting of endemicity: identification of novel risk factors.

Authors:  Erik R Dubberke; Kimberly A Reske; Yan Yan; Margaret A Olsen; L Clifford McDonald; Victoria J Fraser
Journal:  Clin Infect Dis       Date:  2007-12-15       Impact factor: 9.079

9.  Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors.

Authors:  S B Debast; N Vaessen; A Choudry; E A J Wiegers-Ligtvoet; R J van den Berg; E J Kuijper
Journal:  Clin Microbiol Infect       Date:  2009-03-23       Impact factor: 8.067
  9 in total
  1 in total

1.  Efficacy of a Postprescription Review of Broad-Spectrum Antimicrobial Agents With Feedback: A 4-Year Experience of Antimicrobial Stewardship at a Tertiary Care Center.

Authors:  Hitoshi Honda; Shutaro Murakami; Yasuaki Tagashira; Yuki Uenoyama; Kaoru Goto; Akane Takamatsu; Shinya Hasegawa; Yasuharu Tokuda
Journal:  Open Forum Infect Dis       Date:  2018-11-22       Impact factor: 3.835
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.